Eric's Risk Assessment<p>Ensitrelvir Prevents <a href="https://zeroes.ca/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>COVID19</span></a> Infection as Post Exposure Prophylaxis</p><p>&gt; Japan-based Shionogi presented results for its investigational antiviral, ensitrelvir, that demonstrated a 67% reduction in the risk of developing COVID-19 in uninfected individuals treated after exposure, compared to a placebo at day 10</p><p><a href="https://www.contagionlive.com/view/ensitrelvir-prevents-covid-19-infection-as-post-exposure-prophylaxis" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">contagionlive.com/view/ensitre</span><span class="invisible">lvir-prevents-covid-19-infection-as-post-exposure-prophylaxis</span></a></p><p><a href="https://zeroes.ca/tags/sars2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>sars2</span></a> <a href="https://zeroes.ca/tags/sarscov2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>sarscov2</span></a> <a href="https://zeroes.ca/tags/antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>antiviral</span></a></p>